深圳惠泰医疗器械股份有限公司 2025 年度业绩快报公告 证券代码：688617 证券简称：惠泰医疗 公告编号：2026-007 | 项目 | 本报告期 | 上年同期 | 增减变动幅 度（％） | | --- | --- | --- | --- | | 营业总收入 | 2,583,927,321.09 | 2,065,801,597.74 | 25.08 | | 营业利润 | 943,928,555.84 | 753,691,427.41 | 25.24 | | 利润总额 | 936,290,399.51 | 745,967,278.53 | 25.51 | | 归属于母公司所有者的净利润 | 820,636,582.43 | 673,151,713.17 | 21.91 | | 归属于母公司所有者的扣除非经 常性损益的净利润 | 790,875,930.28 | 643,008,371.94 | 23.00 | | 基本每股收益（元） | 5.82 | 4.80 | 21.25 | | 加权平均净资产收益率 | 28.77% | 30.35% | 减少 个 1.58 百分点 | | | 本报告期末 | 本报 ...

Core Insights - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New and Achieve leading the gains at 3.63% [1] - The Medical Innovation ETF (516820) has seen a net inflow of 12.6971 million yuan over the past three days, with a peak single-day inflow of 6.1732 million yuan [1] - The current phase of brain-computer interface technology is described as an explosive period, with multiple countries, including China, accelerating their strategic positioning in global brain science [1] - AI is transitioning from a supportive role to becoming a core driver of value reconstruction and efficiency revolution in the medical industry, impacting various sectors such as medical imaging and drug development [1] Industry Overview - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

Market Overview - The Shanghai Composite Index increased by 0.41% to close at 4082.07 points, with a weekly high of 4142.56 points [1] - The Shenzhen Component Index rose by 1.39% to 14100.19 points, reaching a peak of 14296.48 points [1] - The ChiNext Index saw a 1.22% increase, closing at 3275.96 points, with a high of 3348.48 points [1] - In the global market, the Nasdaq Composite fell by 2.1%, the Dow Jones Industrial Average decreased by 1.23%, and the S&P 500 dropped by 1.39% [1] - In the Asia-Pacific region, the Hang Seng Index rose by 0.03%, while the Nikkei 225 Index increased by 4.96% [1] New Stock Issuance - Two new stocks were issued during the week: Tongbao Optoelectronics (920168.BJ) on February 9, 2026, and Tongling Technology (920187.BJ) on February 11, 2026 [2] Margin Trading - The total margin trading balance in the Shanghai and Shenzhen markets was 25,797.58 billion yuan, with a financing balance of 25,640.12 billion yuan and a securities lending balance of 157.46 billion yuan [3] - The margin trading balance decreased by 752.4 billion yuan compared to the previous week [3] - The Shanghai market's margin trading balance was 13,113.7 billion yuan, down by 356.66 billion yuan, while the Shenzhen market's balance was 12,683.88 billion yuan, down by 395.74 billion yuan [3] - A total of 3,486 stocks had margin buying, with 184 stocks having over 1 billion yuan in buying amounts, led by Xinyi Technology (103.25 billion yuan), Zhongji Xuchuang (98.63 billion yuan), and Wangsu Science and Technology (74.22 billion yuan) [3] Fund Issuance - Seven new funds were issued during the week, including Guoshou Anbao Enhanced Return Bond E, Huafu Anhua Bond D, Dongfanghong Monetary F, Bank of China Health Life Mixed C, Huitianfu Tiantianle Double Win Bond E, Nuoan Selected Return Mixed C, and Changsheng Electronic Information Theme Mixed C [5] Share Buybacks - Eight companies announced share buybacks, with the highest amounts executed by Luxshare Precision (002475), Hengyi Petrochemical (000703), Linyang Energy (601222), Kaiying Network (002517), and Huitai Medical (688617) [7] - The industries with the highest buyback amounts were electronics, petroleum and petrochemicals, and public utilities [8]

这家智慧招采领域的龙头企业累计回购股份182.72万股，占公司总股本的0.57%，回购成交的最高价为31.15元/股，最低价为24.21元/股，回购均价为27.01元/ 股，支付的资金总额达到4935.67万元。 回购方案于2025年9月24日启动，计划使用自有资金3000万元至5000万元，实际执行金额接近上限。 这些回购的股份将全部用于员工持股计划或股权激励。 春节前的资本市场总是充满变数，当港股市场特别是互联网科技股表现疲软时，A股市场却出现了另一番景象。 2026年1月下旬至2月上旬，就在春节假期临近之际，9家行业龙头公司不约而同地采取了行动。 新点软件在2026年2月13日发布公告，宣布公司已完成股份回购计划。 回购的股份将在未来用于股权激励、员工持股计划或转换公司可转债。 衢州东峰新材料集团在2026年2月12日披露了回购报告书。 这家国资控股的新材料与医药包装企业计划使用自有资金，通过集中竞价交易方式回购公司股 份，回购金额区间为5000万元至1亿元。 回购价格上限设定为6.48元/股，按照这个价格测算，预计回购股份数量约为771.60万股至1543.21万股，占公司总股 本的比例为0.40%至 ...

Group 1 - The company plans to repurchase shares using its own funds, with an amount between 150 million to 200 million yuan, aimed at employee incentives and enhancing investor confidence [1] - The first repurchase was executed on February 11, 2026, with 77,000 shares bought back at a total cost of approximately 18.61 million yuan [1] - The recent opening of the national drug procurement may have indirect effects on the medical device industry, although the company's core business focuses on electrophysiology and interventional devices [1] Group 2 - Huayuan Securities initiated coverage on the company on February 13, 2026, giving it a "buy" rating, with expected compound annual growth rates for revenue and net profit exceeding 24% from 2025 to 2027 [2] - In the past 90 days, four institutions have rated the company, with three giving a "buy" and one an "overweight" rating, indicating positive expectations from analysts [2]

Group 1 - Company Huatai Medical announced on February 11 that it repurchased 77,000 shares through centralized bidding, accounting for approximately 0.05% of the total share capital of about 141 million shares [1] - The highest price for the repurchase was 242.27 yuan per share, while the lowest price was 241 yuan per share, with a total payment of approximately 18.61 million yuan [1] Group 2 - The emergence of a new Chinese video model, described as "the strongest on the surface," can generate 15-second videos for commercial delivery with just a few prompt words, leading to a surge in film and television stocks [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 证券代码：688617 证券简称：惠泰医疗 公告编号：2026-006 深圳惠泰医疗器械股份有限公司 关于以集中竞价方式首次回购股份的公告 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次实施回购股份情况公告如下： 2026 年 2 月 11 日，公司通过集中竞价交易方式首次回购公司股份 77,000 股， 占公司总股本 141,030,049 股的比例约为 0.05%，回购成交的最高价为 242.27 元/ 股，最低价为 241.00 元/股，支付的资金总额为人民币 18,605,600.00 元（不含印花 税、交易佣金等交易费用）。 本次回购股份符合相关法律法规及公司回购股份方案的规定。 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2026/2/10，由董事会提议 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2026 年 2 月 9 12 月 8 | ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-005 二、公司前十名无限售条件股东持股情况 | 序号 | 股东名称 | 持股数量（股） | 占公司总股 | | --- | --- | --- | --- | | | | | 本比例（%） | | 1 | 深圳迈瑞科技控股有限责任公司 | 32,508,228 | 23.05 | | 2 | 成正辉 | 23,551,232 | 16.70 | | 3 | 香港中央结算有限公司 | 8,380,590 | 5.94 | | 4 | 珠海彤昇投资合伙企业（有限合伙） | 4,909,960 | 3.48 | | 5 | 招商银行股份有限公司－华夏上证科创板 | 50 3,188,292 | 2.26 | | | 成份交易型开放式指数证券投资基金 | | | | 6 | 中国银行股份有限公司－华宝中证医疗交易 | 2,577,144 | 1.83 | | | 型开放式指数证券投资基金 | | | | 7 | 徐轶青 | 2,520,320 | 1.79 | | 8 | 中国银行股份有限公司－易方达蓝筹精选混 | 2,500,000 | 1.77 | ...

Group 1 - On February 10, brokerages set target prices for listed companies with notable increases for Kehua Data, Nanwei Medical, and Fulete, with target price increases of 19.70%, 18.54%, and 14.09% respectively, belonging to the other power equipment, medical devices, and photovoltaic equipment industries [1][3] - A total of 21 listed companies received brokerage recommendations on February 10, with companies like Bailong Oriental, Chiplink Integration, and Tianrun Industrial each receiving one recommendation [3] - One company, Haomai Technology, had its rating upgraded from "Hold" to "Buy" by Guotou Securities on February 10 [4][5] Group 2 - Three companies received initial coverage on February 10, including Xin'ao Co., which was rated "Buy" by Shenda Securities, Bichu Electronics rated "Increase" by Jianghai Securities, and Huitai Medical rated "Buy" by Huayuan Securities [5][6] - The companies receiving initial coverage are in the textile manufacturing, computer equipment, and medical device industries [6]

Core Viewpoint - The China Securities Medical Index (399989) closed at 7197.66 points on February 10, with a 0.5% increase and a trading volume of 19.639 billion yuan, indicating a stable performance in the medical sector [1]. Group 1: Index Performance - The index saw 25 constituent stocks rise, with Huitai Medical leading the gains at 5.15%, while 24 stocks declined, with Huaxi Biological leading the losses at 3.36% [1]. - The turnover rate for the index was 1.82%, reflecting moderate trading activity [1]. Group 2: Capital Flow - The net inflow of main funds into the constituent stocks of the index totaled 554 million yuan, indicating positive institutional interest [2]. - Retail investors experienced a net outflow of 416 million yuan, suggesting a cautious sentiment among individual investors [2]. - Speculative funds saw a net outflow of 159 million yuan, indicating reduced trading activity from this segment [2].